Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir versus lamivudine + adefovir in lamivudine-resistant chronic hepatitis B with undetectable viral load
2011-000629-55Phase 4Completed
- Sponsor
- Manuel RodrÃguez GarcÃa
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tenofovir disoproxil fumarate, lamivudine and adefovir dipivoxil in Chronic Hepatitis B (CHB) (2 arms), sponsored by Manuel RodrÃguez GarcÃa. Primary endpoint: Sustained virological response at 48 weeks. Started Nov 2011; status: completed.
02
Drugs
tenofovir disoproxil fumaratelamivudineadefovir dipivoxil
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2011-000629-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000629-55.